Sarepta (SRPT) calls active after FDA approves eteplirsen

September 19, 2016 10:03 AM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Sarepta Therapeutics (NASDAQ: SRPT) September and October 43 calls are active after a post to the website of the FDA indicated that the regulator granted approval for eteplirsen, the company's treatment of Duchenne muscular dystrophy.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Options, Trader Talk

Add Your Comment